Singapore, Oct. 12 -- South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced a strategic collaboration with Discovery Life Sciences, a global leader in biospecimens and specialty laboratory services, to expand the adoption of the Lunit SCOPE suite, the company's AI-powered pathology platform, across biopharmaceutical research.

Discovery brings more than 25 years of assay expertise and has delivered biomarker services for more than 2,000 clinical trial programs while currently supporting over 350 active trial programs through its end-to-end specialty laboratory services across the drug development lifecycle.

Through the collaboration, Discovery and Lunit will work together with biop...